基因检测在成人CKD诊断与管理中的临床效用
RenaCARE研究是一项单臂、干预性、前瞻性、多中心研究,纳入1623例成人CKD患者,评估385基因肾脏病panel的临床效用。20.8%患者检出阳性遗传发现,其中48.8%获得新诊断或诊断重新分类;90.7%阳性患者的管理因基因结果改变,32.9%发生治疗方案改变。
要点
- 1623例CKD患者中20.8%检出阳性遗传发现,涉及54个基因。
- 阳性患者中48.8%获得新诊断或诊断重新分类。
- 90.7%阳性患者管理因基因检测改变,32.9%治疗方案改变。
核心结论
- 385基因panel基因检测显著细化了CKD临床诊断,并对临床管理产生广泛影响,包括适当的治疗策略。
研究设计与样本
- RenaCARE(NCT05846113)为单臂、干预性、前瞻性、多中心研究,从31家美国社区和学术医疗中心招募成人CKD患者。
- 共纳入1623例CKD患者,涵盖13个预设临床疾病分类,年龄18-96岁,中位年龄55岁。
- 在基因检测前和结果返回后1个月收集医生关于疾病分类和管理的问卷。
主要发现
- 20.8%(n=338)患者检出阳性遗传发现,涉及54个基因。
- 阳性遗传发现患者中48.8%获得新诊断或对先前诊断重新分类。
- 医生报告基因结果改变了90.7%阳性遗传发现患者的管理,其中32.9%报告治疗方案改变。
临床怎么用
- 研究数据支持将更广泛的基因检测panel整合到CKD患者临床诊疗范式中的效用。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
SIGNIFICANCE STATEMENT: Accurate diagnosis of a patient's underlying cause of CKD can influence management and ultimately overall health. The single-arm, interventional, prospective Renasight Clinical Application, Review, and Evaluation study assessed the utility of genetic testing with a 385 gene kidney disease panel on the diagnosis and management of 1623 patients with CKD. Among 20.8% of patients who had positive genetic findings, half resulted in a new or reclassified diagnosis. In addition, a change in management because of genetic testing was reported for 90.7% of patients with positive findings, including treatment changes in 32.9%. These findings demonstrate that genetic testing has a significant effect on both CKD diagnosis and management. BACKGROUND: Genetic testing in CKD has recently been shown to have diagnostic utility with many predicted implications for clinical management, but its effect on management has not been prospectively evaluated. METHODS: Renasight Clinical Application, Review, and Evaluation RenaCARE (ClinicalTrials.gov NCT05846113 ) is a single-arm, interventional, prospective, multicenter study that evaluated the utility of genetic testing with a broad, 385 gene panel (the Renasight TM test) on the diagnosis and management of adult patients with CKD recruited from 31 US-based community and academic medical centers. Patient medical history and clinical CKD diagnosis were collected at enrollment. Physician responses to questionnaires regarding patient disease categorization and management were collected before genetic testing and 1 month after the return of test results. Changes in CKD diagnosis and management after genetic testing were assessed. RESULTS: Of 1623 patients with CKD in 13 predefined clinical disease categories (ages, 18-96; median, 55 years), 20.8% ( n =338) had positive genetic findings spanning 54 genes. Positive genetic findings provided a new diagnosis or reclassified a prior diagnosis in 48.8% of those patients. Physicians reported that genetic results altered the management of 90.7% of patients with a positive genetic finding, including changes in treatment plan, which were reported in 32.9% of these patients. CONCLUSIONS: Genetic testing with a CKD-focused 385 gene panel substantially refined clinical diagnoses and had widespread implications for clinical management, including appropriate treatment strategies. These data support the utility of broader integration of panels of genetic tests into the clinical care paradigm for patients with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: ClinicalTrials.gov, NCT05846113 .
引用
- Dahl NK, Bloom MS, Chebib FT, et al. The Clinical Utility of Genetic Testing in the Diagnosis and Management of Adults with Chronic Kidney Disease. J Am Soc Nephrol. 2023. PMID: 37794564. doi:10.1681/ASN.0000000000000249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。